Paratek Pharmaceuticals of Boston, Mass., has named Dennis Molnar as director, president and CEO, and Evan Loh, MD, as chief medical officer and chairman of the board of directors.
Molnar, formerly Paratek's vice president of corporate development, has 19 years of experience in the pharmaceutical and biotechnology industries, working in a variety of capacities, including business development, management, finance and consulting. Before joining Paratek in 2001, he served as president of JBI Associates, a software and consulting firm providing services to hospital pharmacies. Molnar has also served as director of finance and business development at Magainin Pharmaceuticals.
Loh comes to Paratek from Pfizer where he served as senior vice president of development and strategic operations, worldwide R&D. Prior to joining Pfizer in 2009, Loh was vice president of clinical R&D at Wyeth, where he had global responsibility for scientific, strategic and operational leadership of clinical development efforts across multiple therapeutic areas. Loh is the 2006 recipient of the Heroes of Chemistry award from the American Chemical Society for his leadership role at Wyeth in the clinical development of Tygacil, a novel glycylcycline broad-spectrum antibiotic. Loh has served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine.